[go: up one dir, main page]

AU2600800A - Promotion or inhibition of angiogenesis and cardiovascularization - Google Patents

Promotion or inhibition of angiogenesis and cardiovascularization

Info

Publication number
AU2600800A
AU2600800A AU26008/00A AU2600800A AU2600800A AU 2600800 A AU2600800 A AU 2600800A AU 26008/00 A AU26008/00 A AU 26008/00A AU 2600800 A AU2600800 A AU 2600800A AU 2600800 A AU2600800 A AU 2600800A
Authority
AU
Australia
Prior art keywords
cardiovascularization
angiogenesis
promotion
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26008/00A
Inventor
Avi J. Ashkenazi
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Kenneth J. Hillan
Sophia S. Kuo
Melanie R Mark
Scot A. Marsters
Nicholas F. Paoni
Robert M. Pitti
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2600800A publication Critical patent/AU2600800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU26008/00A 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization Abandoned AU2600800A (en)

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
USNOTGIVEN 1998-02-02
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
WOUS9905028 1999-03-08
US12395799P 1999-03-12 1999-03-12
US60123957 1999-03-12
US13428799P 1999-05-14 1999-05-14
US60134287 1999-05-14
WOUS9912252 1999-06-02
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14103799P 1999-06-23 1999-06-23
US60141037 1999-06-23
US14475899P 1999-07-20 1999-07-20
US60144758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60145698 1999-07-26
WOUS9920111 1999-09-01
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
WOUS9920594 1999-09-08
PCT/US1999/020594 WO2000015666A2 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumors
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOUS9921090 1999-09-15
WOUS9921547 1999-09-15
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
WOUS9923089 1999-10-05
WOUS9928409 1999-11-30
WOUS9928313 1999-11-30
WOUS9928565 1999-12-02
WOUS9928564 1999-12-02
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
AU2600800A true AU2600800A (en) 2000-09-28

Family

ID=27537684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26008/00A Abandoned AU2600800A (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization

Country Status (2)

Country Link
AU (1) AU2600800A (en)
WO (1) WO2000053753A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284550A1 (en) 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
US20030027985A1 (en) 1997-06-16 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7169906B2 (en) 1997-09-17 2007-01-30 Genentech, Inc. PRO211 polypeptides
US6974689B1 (en) 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
EP1108042B1 (en) 1998-08-07 2008-11-26 Immunex Corporation Molecules designated b7l-1
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
EP1247863B1 (en) * 1998-08-11 2005-12-28 Genentech, Inc. Snake venom protein A homologue and nucleic acid encoding the same.
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
AU2001273077A1 (en) * 2000-06-30 2002-01-14 Millennium Pharmaceuticals, Inc. Slgp protein and nucleic acid molecules and uses therefor
US7045299B2 (en) 2000-07-18 2006-05-16 Takeda Pharmaceutical Company Limited Physiologically active peptide and use thereof
ATE544855T1 (en) * 2000-10-16 2012-02-15 Genentech Inc WISP POLYPEPTIDES, AND THEIR THERAPEUTIC USES
JP2004532609A (en) 2000-11-03 2004-10-28 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア Prokineticin polypeptides, related compositions and methods
WO2002057443A1 (en) * 2001-01-22 2002-07-25 Takeda Chemical Industries, Ltd. Process for producing zaq ligand
EP1403367A4 (en) * 2001-06-08 2005-08-17 Sankyo Co Method of testing drug for treating or preventing diseases such as hyperlipemia
WO2003006687A2 (en) * 2001-07-10 2003-01-23 Medigene Ag Novel target genes for diseases of the heart
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2003083114A1 (en) * 2002-03-28 2005-08-04 アステラス製薬株式会社 Angiopoietin-related growth factor
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
CA2577102A1 (en) 2004-08-25 2006-03-09 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ZA200807714B (en) * 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
MX9605109A (en) * 1994-04-26 1997-08-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis.
WO1997019172A1 (en) * 1995-11-17 1997-05-29 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide
JP3989589B2 (en) * 1997-05-14 2007-10-10 旭化成株式会社 Vascular cell regulator

Also Published As

Publication number Publication date
WO2000053753A2 (en) 2000-09-14
WO2000053753A3 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
AU2600800A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU6465400A (en) Inhibition of action potentials
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU3791601A (en) Treatment of coal
AU2596700A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU2567300A (en) Inhibition of angiogenesis with epigallocatechin-3-gallate
AU6566098A (en) Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
AUPQ429399A0 (en) Oxidized apolipoproteins and methods of use
AU9484398A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU4369000A (en) Inhibition of complement action
IL140324A0 (en) Inhibition of transcription factor nf-kb
AU7601400A (en) Treatment and prevention of hepatic disorders
AU7271600A (en) Quinazolinone and azaquinazolinone derivatives
IL141537A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU4440199A (en) Methods and compositions for inhibition of angiogenesis
AU5571799A (en) Angiogenesis inhibitors and uses thereof
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
AUPQ180499A0 (en) Beta-amyloid peptide inhibitors
AU2002215032A1 (en) Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
EP1229913A4 (en) Substituted 1-benzazepines and derivatives thereof
AU2001251631A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
AU1747100A (en) Promotion or inhibition of angiogenesis and cardiovascularization
HUP0301797A3 (en) Inhibition of angiogenesis and tumor growth
AU5646300A (en) Methods of stimulating angiogenesis
IL142742A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase